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Abstract Bevacizumab (BEV) has demonstrated anti-
tumor activity in patients with recurrent glioblastoma
(rGB). Given the unmet need for active therapeutic options
in rGB patients, a medical need program was initiated by
the Belgian competent authorities. Between November
2010 and February 2013, a total of 313 patients with rGB
initiated treatment with BEV administered at a dose of
10 mg/kg every 2 weeks. All patients had failed prior
treatment with at least radiation therapy and temozolomide
and the majority of patients (70 %) were treated with
corticosteroids at baseline. Patients received a median of 6
BEV administrations (range 1–53). Overall, BEV was well
tolerated. During BEV treatment the WHO-Performance
Score (WHO-PS) improved in 59 patients (19 %) and
stabilized for at least 6 weeks in an additional 139 (44 %)
patients. Corticosteroid treatment could be stopped in 16 %
or reduced in dose in 32 % of patients. The best objective
tumor response rate using RANO criteria (investigator’s
assessment) was 3.5 % CR, 22 % PR, 38 % SD and 37 %
PD. The median and 6-month PFS were 13 weeks (95 %
CI 12.7–14) and 27.3 % (95 % CI 22.3–32.5), median and
6-month OS rates were 26 weeks (23–29) and 52 %
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(46.4–58.6), respectively. WHO-PS (0–1 vs. 2–3) and
baseline steroid use were significantly correlated with PFS
and OS. Our observations support the use of BEV as a
monotherapy for patients with rGB who have no alternative
treatment options. Optimal benefit from BEV treatment is
likely to be obtained when treatment is initiated before the
performance status deteriorates to two or less.
Keywords Recurrent glioblastoma  Bevacizumab 
Corticotherapy  WHO-PS
Introduction
Glioblastoma (GB) is the most frequent and most lethal
subtype of central nervous system glioma. Current standard
treatment consists of maximal safe resection, postoperative
fractionated radiation therapy (30 9 2 Gy) with concomi-
tant daily temozolomide (TMZ) followed by six cycles of
adjuvant TMZ administered 5 out of 28 days [1]. The
median overall survival (OS) of patients treated with this
regimen is 14.6 months; OS is 27.2 % at 2 years and 9.8 %
at 5 years [2]. At recurrence, no standard of care has been
established and results of investigational cytotoxic thera-
pies have been notoriously disappointing. Salvage thera-
pies for rGB have produced 6-month progression-free
survival (PFS) rates in the order of 10–15 % and a best
overall response rate of 5–10 %. Median OS from the time
of recurrence varies between 25 and 30 weeks [3–5].
The vascular endothelial growth factor (VEGF) and
VEGF-receptors are key molecular mediators of tumor-
associated neo-angiogenesis. GB’s are highly angiogenic
tumors that typically express increased levels of VEGF;
mutation and amplification of the VEGFR2 gene have been
described in a significant percentage of GBs [6–9]. VEGF-
A has been correlated with increasing glioma grade and is
also associated with poor outcome among GB patients [10–
12]. Bevacizumab (BEV; Avastin, Roche, Basel, Switzer-
land) is a humanized IgG1 monoclonal antibody that binds
and inhibits VEGF. Its anti-tumor activity in rGB was
demonstrated in several prospective uncontrolled clinical
trials and retrospective studies, indicating also that BEV
improves PFS as compared to historical controls [13–21].
The largest prospective trial in recurrent GB reported a
response rate of 28.2 % for BEV as a single agent and
37.8 % when used in combination with irinotecan [13].
The PFS of both study arms on this trial compared favor-
ably with historic controls (6-month progression-free sur-
vival rates were 42.6 and 50.3 %, respectively) while the
median OS time (8.7 and 9.2 months, respectively) was
within the range of historical data. Two recently published
clinical trials using BEV in the first-line setting, in com-
bination with standard radio-chemotherapy, also demon-
strated an improvement of PFS but not OS [22, 23]. On
May 5, 2009 the FDA granted accelerated approval to BEV
as a single agent for the treatment of patients with rGB
while the European Medicines Agency (EMA) provided a
negative opinion on the request for marketing authorization
of Avastin in this indication within the EU. Given the
unmet need for active therapeutic options in GB patients
who experience a recurrence of their disease, a medical
need program was initiated by the Belgian competent
authorities, allowing the use of BEV monotherapy for this
patient population. Fifteen medical centers with expertise
in the treatment of GB and the use of anti-angiogenic
therapies were authorized to enroll and treat patients.
Clinical data from this program was prospectively col-
lected and analyzed by academic investigators of the
Universitair Ziekenhuis Brussel in collaboration with
experts of the Belgian competent authorities (FAGG/
AFMPS).
Materials and methods
Medical need program
The use of BEV in this medical need program was
restricted to medical centers with expertise in the treatment
of patients with GB and in the use of anti-VEGF therapies.
The prescribing medical doctor needed to have prior
experience in treating neuro-oncological patients in the
context of a clinical trial, was required to have made sci-
entific contributions in the field of neuro-oncology and had
to commit to completing the case report forms on a regular
basis.
Patient eligibility criteria
Patients aged 18 years or older with recurrent primary or
secondary glioblastoma were eligible under the condition
that they had failed prior therapy with surgery, radiation
therapy, and temozolomide. The diagnosis of glioblastoma
was established by a local pathologist according to the
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2007 WHO-criteria. Patients were considered to be diag-
nosed with ‘‘secondary glioblastoma’’ when they had pre-
viously been diagnosed with a low-grade (WHO-grade II)
or anaplastic (WHO-grade III) glioma and subsequently
diagnosed with a WHO-grade IV glioma.
No alternative treatment options were remaining in the
opinion of the investigator and the patient was not eligible
for or refused participation in an ongoing clinical trial.
Patients who had MRI evidence of recent intracranial
hemorrhage, evidence of bleeding diathesis or coagulopa-
thy, uncontrolled hypertension, a history of arterial
thrombo-embolism less than 6 months before the first
administration, history of gastro-intestinal perforation or
fistula, or who had non-healing wounds were ineligible for
the program. Waivers allowing participation of patients
who did not fulfill all eligibility criteria could be applied
for. These requests were evaluated by two to three experts
and a waiver was granted if at least two experts agreed to
grant permission. An informed consent, approved by the
ethics committees of all participating medical centers, was
signed by each patient before initiation of treatment.
Data collection and trial management
An electronic case report form (eCRF) was used for data
collection. Collected data were verified and analyzed by an
academic expert in collaboration with an expert from the
FAGG/AFMPS. In order to periodically assess safety and
efficacy of BEV in this indication, every three months an
interim analysis was made and presented to the competent
authorities at a monitoring meeting. The decision whether
or not to pursue the program was reevaluated at every
meeting, based on the results. Baseline patient character-
istics that were recorded included age, sex, height, weight,
ethnicity, performance status according to the WHO-PS
scale, former medical and surgical history with relation to
their glioma, use and dosage of corticosteroids [24].
Bevacizumab treatment and patient evaluation
Bevacizumab was administered intravenously at a dose of
10 mg/kg every 2 weeks. Physical examination including
neurological examination and blood pressure measurement
was performed biweekly. MRI was performed at baseline
(within 4 weeks before initiating BEV), then six and
12 weeks after start of BEV treatment and every 12 weeks
thereafter. Adverse events, related or not, were recorded
and graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events
(CTCAE Version 4.0) [25]. Response assessments
according to RANO criteria were performed every 6 weeks
or sooner in case of clinical deterioration [26].
Statistical analysis
Differences in baseline characteristics between responders
and non-responders were evaluated using Chi-square test
for categorical variables and ANOVA for ordinal variables.
The cumulative incidence of a first occurrence of an
adverse event was plotted over time. PFS was defined as
the time from initiation of BEV treatment to progression or
death and was censored at the last clinical evaluation for
patients who were free from progression at the latest fol-
low-up. OS was defined as the time from initiation of
treatment until death and censored at the time of latest
follow-up for surviving patients. Probability of progres-
sion-free and OS was calculated using the Kaplan–Meier
method.
Probability of survival was compared between sub-
groups using the log rank test. The Cox logistic regression
model was used to estimate the hazard ratio (HR) of
baseline characteristics (age, WHO-PS, tumor location,
primary versus secondary GB, number of previous lines of
medical treatment, number, and type of surgeries).
Results
Characteristics of the patient population
Between November 2010 and February 2013, 313 patients
with rGB initiated BEV treatment in the Belgian MNP.
Patients were recruited at fifteen medical centers (Table 1).
Median number of patients recruited per center was 19
Table 1 Patients recruited per center
Participating center Number of patients recruited
UZ Leuven 44
AZ Sint Lucas 42
CHU Sart-Tilman 33
UZ Brussel 28
ZH Oost Limburg 26
UCL St Luc 24
ZNA Middelheim 24
ULB Erasme 19
UCL Mont-Godine 16
Virga Jesse 15
UZ Antwerpen 13
Grand hopital de Charleroi 11
H. de Jolimont 8
OLV aalst 5
HHZ roeselaere 5
Total 313
744 J Neurol (2015) 262:742–751
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(range 5–44). The median age was 55 years (range 16–82).
Nineteen percent of patients were elderly (age 65 and
older). The majority of patients were male (61 %), of
Caucasian ethnicity (91 %), had been diagnosed initially
with primary glioblastoma, had a baseline WHO-PS of 0,
or 1 (75 %), and were treated with corticosteroids (70 %)
(Table 2). A partial or complete tumor resection had been
performed at initial diagnosis in 90 % of patients; the
remaining 10 % had only undergone biopsy. Almost half of
all patients (49 %) had undergone at least one surgical
resection for recurrence. All patients had previously been
treated with radiation therapy and temozolomide chemo-
therapy. Seventy-one percent of patients had failed one or
more prior salvage treatments for recurrent disease.
Besides temozolomide, patients had been most frequently
systemically pretreated with autologous dendritic cell
therapy (20 % of patients) and nitrosurea-based chemo-
therapy regimens (18 % of patients).
Treatment disposition of bevacizumab
As of March 2014, 309 out of 313 patients had ended BEV
treatment. Median number of BEV administrations was 6
(range 1–53; administered doses ranged between 390 and
1,350 mg). BEV treatment was ended because of pro-
gression of disease in the majority (83 %) of patients. In
6.7 % of patients, an adverse event led to the interruption
of treatment. In respectively 4.8 and 2.5 % of patients the
decision to stop BEV treatment was taken by the patient or
treating physician in the absence of progression.
Adverse events
A total of 213 adverse events (AE) in 119 patients were
considered to be related or possibly related to BEV by the
treating physician (cumulative incidence of any treatment
related adverse event: 38 %) (Table 3). The most fre-
quently encountered BEV related AE were hypertension
(12,5 %), proteinuria (9 %), fatigue (8 %), infection (8 %),
and headache (7 %). The majority of AE (76 %) were of
grade 1 or 2. There were 36 patients (11.5 %) who expe-
rienced a grade 3–5 AE. The 11 life-threatening AE (grade
4) concerned three patients with an intracranial hemor-
rhage, three patients with severe metabolic disturbances
(hypernatremia, hyperkalemia, and hyperglycemia), one
patient with a myocardial infarction, and two patients with
septicemia; all 3 fatal (grade 5) AE concerned thrombo-
embolic events. The cumulative incidence of first occur-
rences of AE of grade 1–2 or grade 3–5 over time is rep-
resented in Fig. 1.
Corticosteroid disposition and performance status
during bevacizumab treatment
Of all patients taking corticosteroids at the time of initi-
ating BEV (219 patients), the dose of corticosteroids could
be tapered in 106 (48 %) during BEV treatment. Among
these patients, steroids could be stopped completely in 36
(16 %).
An improvement of the performance score according to
the WHO-classification (WHO-PS) on at least one mea-
surement during the course of BEV treatment was reported
for 19 % of patients. For an additional 44 %, a stable
clinical status was obtained for at least six-weeks. In 37 %
Table 2 Baseline patient characteristics
No. of patients (%)
Total 313 (100)
Gender
Male 195 (62)
Female 118 (38)
Age (years)
\65 253 (81)
[65 60 (19)
Ethnicity
Caucasian 294 (91)
Arabic/North-African 12 (6)
Other 7 (3)
Anatomical tumor localization
Frontal 102 (33)
Temporal 87 (28)
Parietal 65 (21)
Occipital 23 (7.5)
Multifocal 15 (4.9)
Other 21 (6.7)
Histopathology
Primary glioblastoma 229 (73)
Secondary glioblastoma 84 (27)
Prior systemic therapies
Temozolomide 313 (100)
Dendritic cell therapy 66 (21)
Nitrosurea 60 (19)
Other 24 (8)
Baseline WHO-PS
0 30 (10)
1 204 (65)
2 57 (18)
3 12 (4)
Unknown 10 (3)
Baseline corticosteroid use
Yes 208 (67)
No 98 (31)
Unknown 7 (2)
J Neurol (2015) 262:742–751 745
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of patients a worsening of their WHO-PS was reported
after initiating BEV.
Tumor response by RANO criteria (investigator
assessment)
A complete response by RANO was reported for 3.5 % and
a partial response for 22 % of patients (best overall response
rate of 25 %). A stabilization of disease for at least 6 weeks
following the initiation of BEV was reported for 37 % of
Table 3 Adverse events
considered related or possibly
related to bevacizumab
treatment
CTCAE v4.0 Grade
Total 1 2 3 4 5
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Hypertension 39 (12.5) 10 (3.2) 19 (6.1) 10 (3.2) 0 (0.0) 0 (0.0)
Proteinuria 28 (8.9) 20 (6.4) 5 (1.6) 3 (1.0) 0 (0.0) 0 (0.0)
Fatigue 24 (7.7) 10 (3.2) 10 (3.2) 4 (1.3) 0 (0.0) 0 (0.0)
Infection 24 (7.7) 2 (0.6) 11 (3.5) 9 (2.9) 2 (0.6) 0 (0.0)
Headache 21 (6.7) 10 (3.2) 10 (3.2) 1 (0.3) 0 (0.0) 0 (0.0)
Epilepsy 20 (6.4) 5 (1.6) 7 (2.2) 7 (2.2) 1 (0.3) 0 (0.0)
Diarrhea 13 (4.2) 5 (1.6) 7 (2.2) 1 (0.3) 0 (0.0) 0 (0.0)
Thrombocytopenia 13 (4.2) 4 (1.3) 5 (1.6) 4 (1.3) 0 (0.0) 0 (0.0)
Hoarseness 12 (3.8) 10 (3.2) 2 (0.6) 0 (0.0) 0 (0.0) 0 (0.0)
Deep venous thrombosis 9 (2.9) 0 (0.0) 6 (1.9) 2 (0.6) 0 (0.0) 1 (0.3)
Epistaxis 9 (2.9) 7 (2.2) 2 (0.6) 0 (0.0) 0 (0.0) 0 (0.0)
Visual deterioration 9 (2.9) 1 (0.3) 4 (1.3) 4 (1.3) 0 (0.0) 0 (0.0)
Intracranial hemorrhage 4 (1.3) 1 (0.3) 0 (0.0) 0 (0.0) 3 (1.0) 0 (0.0)
Wound dehiscence 4 (1.3) 1 (0.3) 2 (0.6) 1 (0.3) 0 (0.0) 0 (0.0)
Pulmonary embolism 2 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.6)
Ischemic stroke 2 (0.6) 0 (0.0) 0 (0.0) 2 (0.6) 0 (0.0) 0 (0.0)
Fig. 1 Cumulative adverse
event rate for the time to first
occurrence of an AE of grade
1–2 or grade 3–5
Table 4 Best tumor response by RANO (investigator assessment)
Tumor response No. of patients (%)
CR 11 (3.5)
PR 69 (22)
SD 118 (37.7)
PD 115a (36.7)
Total 313 (100)
a PD was documented by MRI in 79 patients, 36 patients were
considered PD based on clinical observations only
746 J Neurol (2015) 262:742–751
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cases (Table 4). No statistically significant correlation
(p [ 0.05) was found between tumor response and age,
height, weight, gender, previous lines of surgical therapy,
biopsy versus surgical resection, anatomical location of
tumor, primary versus secondary GBM, baseline cortico-
steroid use or baseline WHO-performance status.
Survival
The median and 6-month survival rates with their respec-
tive 95 % confidence intervals were 13 weeks (12–14) and
27 % (22–32) for PFS, and 26 weeks (23–29) and 52 %
(46–58) for OS (Fig. 2). PFS and OS were not significantly
correlated with age, gender, previous lines of surgical
therapy, biopsy-only at primary diagnosis versus one or
more surgical resections, or with the specific anatomical
localization of the tumor (frontal, temporal, occipital,
parietal, or other). Patients with a multifocal rGB had a
numerically shorter median PFS (7 vs. 13 weeks) and
median OS (11 vs. 26 weeks), but the survival probability
was not significantly different (Log Rank p [ 0.05).
Patients receiving corticosteroids at baseline and patients
with a baseline WHO-PS of 2 or 3 (vs. 0 or 1) had a
significantly worse PFS and OS (Fig. 3; Table 5). In a
multivariate Cox logistic regression model, both WHO-PS
and steroid use were retained as independent baseline co-
variables for PFS and OS. In a stratified analysis of elderly
(age 65 or older) versus non-elderly (age 64 or younger)
patients, baseline corticosteroid use was significantly cor-
related with PFS and OS only in non-elderly patients but
lost its significance in elderly patients. Baseline WHO-PS
(0 or 1 vs. 2 or 3) was significantly correlated with PFS and
OS in both subgroups. In a multivariate Cox logistic
regression model for non-elderly patients, baseline corti-
costeroid use was retained as the only independent prog-
nostic factor for PFS and both WHO-PS and baseline
steroid use both were retained as independent baseline co-
variables for OS (Table 5).
Discussion
This analysis of the patient outcome in the Belgian MNP of
bevacizumab for rGB is one of the largest series on rGB
Fig. 2 Kaplan-Meier
progression-free, and overall
survival probability curves
J Neurol (2015) 262:742–751 747
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patients treated with single-agent BEV. Compared to pre-
viously published clinical trial results with BEV as a single
agent [13, 16, 27] or in combination with cytotoxic che-
motherapy [17–19], our patient cohort is comparable in
terms of age, gender, and ethnicity. In contrast to most
prospective clinical trials that only investigated BEV in
rGB patients at first or second recurrence and with a
baseline Karnofsky performance score of 70 or higher [13,
16, 27], our patient population was more extensively pre-
treated with 71 % of patients having failed more than one
line of medical treatment and 39 % of patients having
undergone more than one surgical resection. Also the
baseline performance status was worse in our patient
population with 25 % of patients having a WHO-PS of 2 or
3 at baseline. Our patient group might therefore be more
representative for the population of rGB patients that is
treated with BEV in daily clinical practice when its use is
restricted to patients who have no other treatment option
available.
BEV was generally well tolerated, and the pattern of
treatment related adverse events reflects that of previously
reported prospective clinical trials [13]. The three fatal
(grade 5) AE (1 % incidence) that were possibly related to
BEV all concerned fatal thrombo-embolic events. Addi-
tionally, 9 patients (2.8 %) were diagnosed with a non-fatal
deep venous thrombosis. The cumulative incidence of
thrombo-embolic events was 3.6 %. These findings are
comparable to the incidence of thrombo-embolic events in
the BRAIN study, where this AE occurred in 3.6 % of the
patients treated with single-agent BEV [13]. Considering
that cancer patients, and GB patients in particular, are
known to have a higher risk for thrombo-embolism, we
conclude that the potential increase in risk for thrombo-
embolic events during BEV therapy remains acceptable
outside the setting of a prospective clinical trial [28].
BEV monotherapy in patients with rGB was reported to
result in tumor response rates in the range of 28–58 % and
6-month PFS rate of 16–42 % [29]. The response rate of
25 % and 6-month PFS of 27 %, observed in the Belgian
medical need program, are in range with these data. The
use of RANO criteria for assessment of response may
explain why the response and PFS rate is at the lower end
Fig. 3 Kaplan-Meier survival
probability curves by baseline
WHO-PS
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of the spectrum as tumor response evaluations that are
based only on gadolinium contrast enhanced tumor volume
may underestimate tumor size and disease progression in
patients treated with BEV. It has been reported that the
RANO criteria allow to detect disease progression
approximately one month earlier as compared to criteria
that do not take T2/flair imaging into account [30]. Nor-
malization of the blood brain barrier and reduction of
intracranial vasogenic edema have been well documented
effects of VEGF- or VEGFR-targeted agents. These fea-
tures underlie the high response rates that are observed
early on in the course of treatment [31]. This activity of
BEV also allows to taper the dose or stop corticosteroid
treatment in a significant proportion of patients [13, 27]. In
our series, corticoid doses could be tapered in 32 % of
patients and stopped completely in 16 % of patients,
potentially avoiding the well-known side effects of long-
term high dose corticotherapy. Of relevance is our obser-
vation that 19 % of patients in our study population
experienced a transient improvement of their performance
score during the course of BEV treatment, indicating a
clinical benefit from therapy.
Our observations on the activity of BEV in a heavily
pretreated patient cohort support the conclusions made by
Piccioni et al. and Hamza et al. that deferred use of BEV
does not necessarily decrease its efficacy [32, 33]. We also
confirmed prior findings by Tabouret et al. [20] that baseline
WHO-PS correlates with PFS (and OS) and in addition,
identified baseline corticotherapy as a second baseline var-
iable that correlated independently with survival. In the
subgroup of elderly patients, WHO-PS was retained the only
independent baseline variable correlated with PFS (and OS)
while baseline corticotherapy lost its independent prognostic
importance. Consequently, optimal benefit from BEV ther-
apy may be obtained when BEV treatment is initiated before
the performance status deteriorates to two or less.
The 26 weeks median OS obtained for our population
represents no clear improvement compared to historical
control data (25 weeks median OS being the historical
bench-mark for salvage therapies in rGB patients) [3, 34].
Table 5 Correlation of baseline WHO-PS and corticosteroid use with survival in univariate and Cox logistic regression multivariate analysis
All patients (n = 313) PFS (weeks) OS (weeks)
Median (95 % CI) P value (log rank) Median (95 % CI) P value (log rank)
Univariate analysis WHO-PS 0.1 14 (12.4–15.6) 28.6 (25–32)
2.3 11.4 (10.2–12.7) 0.001 19.3 (16–23) \0.001
Corticosteroid use Yes 13 (12.1–13.9) 20.3 (17–23)
No 16.7 (11.5–21.9) 0.007 35.9 (30–41) \0.001
p value HR (95 % CI) p value HR (95 % CI)
Cox regression analysis WHO-PS 0.1 vs 2.3 0.007 0.669 (0.47–0.82) 0.005 0.65 (0.49–0.87)
Corticosteroid use yes vs no 0.031 0.756 (0.58–0.98) \0.001 0.58 (0.44–0.76)
Elderly (n = 60) Median (95 % CI) P value (log rank) Median (95 % CI) P value (log rank)
Univariate analysis WHO-PS 0.1 22.9 (9.3–36.4) 27.4 (10.4–44.5)
2.3 9 (5.5–12.5) \0.001 13.1 (7–19.3) 0.005
Corticosteroid use Yes 12.6 (8.4–16.7) 17.1 (12–22.3)
No 23.7 (9.1–38.3) 0.202 34.6 (22.6–46.5) 0.76
Non-elderly (n = 253) Median (95 % CI) P value (log rank) Median (95 % CI) P value (log rank)
Univariate analysis WHO-PS 0.1 13.9 (12.7–15) 28.6 (24.5–32.7)
2.3 12.1 (10.4–13.9) 0.035 19.6 (16.1–23) 0.007
Corticosteroid use Yes 13 (12.1–13.9) 20.4 (17.4–23.5)
No 15.7 (10.6–20.8) 0.016 38.4 (31.9–45) \0.001
p value HR (95 % CI) p value HR (95 % CI)
Cox regression analysis WHO-PS 0.1 vs 2.3 0.1 0.773 (0.6–1) 0.043 0.716 (0.52–0.99)
Corticosteroid use yes vs no 0.017 0.714 (0.5–0.9) \0.001 0.572 (0.42–0.76)
Elderly is defined as age [65 years old
J Neurol (2015) 262:742–751 749
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Inclusion of poor prognosis patients in our cohort is likely
to have negatively influenced the probability for survival.
When considering only patients with WHO 0 or 1 at
baseline, 6-months PFS was 31 % (95 % CI range
25–37 %) and median OS was 29 weeks (95 % CI 25–33),
suggesting that a small to moderate survival advantage
cannot be excluded for this subgroup of rGB patients. Our
finding that other established indicators of poor prognosis
such as older age and number of prior lines of medical or
surgical treatment did not statistically influence survival
outcome in patients treated with BEV mirrors the obser-
vations by Tabouret et al. [20]. It has been suggested that
patients of older age experience a more significant increase
in survival rates [17]. In our observations, age was not
correlated with tumor response or survival following BEV
treatment.
In order to optimize the use of BEV for rGB, future
studies should aim at determining predictive biomarkers
for the benefit from BEV treatment. Clinical factors are
correlated with survival but do not seem to predict for
tumor response in our observations. This finding underlines
the necessity for biomarkers, or imaging-based indicators
as a tool for selection of patients whose tumors are sensi-
tive to BEV [35–37]. In addition, predictive imaging
markers associated with a substantial survival benefit could
also be helpful in making adequate early treatment deci-
sions [38, 39]. It should be noted, however, that within this
indication of rGB patients with no alternative treatment
option and poor life expectancy, most patients are symp-
tomatic at the time of treatment initiation and the clinical
benefit can be readily assessed by clinical follow-up of the
patient. Given the acceptable risk/benefit ratio observed in
this large cohort of patients, this experience supports the
use of BEV as a monotherapy in patients with rGB who
lack alternative treatment options or access to clinical
trials.
Recently, a randomized phase II clinical trial investi-
gating BEV versus lomustine, and the combination of BEV
with lomustine as the first treatment option for rGB indi-
cated a better survival outcome with the combination
therapy [40]. This combination therapy is currently under
investigation in a randomized phase III trial conducted by
the EORTC (ClinicalTrials.gov Identifier: NCT01290939).
If positive, this trial may legitimate the use of BEV in
combination with lomustine as the first option for treatment
of patients with rGB.
Conclusion
Our study of the outcome of patients treated in a MNP of
BEV for rGB in Belgium confirms previous reports that
BEV is an active treatment in this indication and that it can
be used with an acceptable safety profile in patients who
are considered to have no alternative treatment option,
including the possibility for participation in a clinical trial.
The survival of our patient cohort is comparable to that of
historical controls but the observed reduction in corticoid
dependence and the temporary improvement or stabiliza-
tion in performance status in a meaningful subgroup of
patients indicates a clinical benefit from BEV. Baseline
WHO-PS was the only clinical variable that correlated
significantly with survival: patients with a WHO-PS of 0 or
1 had a significantly better outcome in terms of PFS and
OS. As indicated by recent reports on the use of BEV for
rGB, our observations support the notion that its deferred
use may not negatively impact its therapeutic usefulness.
Notwithstanding, an optimal benefit in terms of PFS is
obtained if BEV treatment is initiated before the WHO-PS
deteriorates to 2 or less.
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